Bone mineral density and bone turnover in postmenopausal women treated for breast cancer

Nancy Lauraine Waltman, Carol D. Ott, Janice J Twiss, Gloria J. Gross, Ada M. Lindsey, Timothy Eisdell Moore

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Chemotherapy and endocrine treatments for breast cancer are believed to increase risk of osteoporosis by causing early menopause in premenopausal women and by further depleting estrogen levels in postmenopausal women. Multivariate analyses were used to evaluate the contributions of 7 predictors (age, body mass index [BMI], family history of osteoporosis, months since menopause, past use of chemotherapy, and current use of tamoxifen or aromatase inhibitors) in explaining variability in bone mineral density (BMD) at the hip and the spine and bone turnover in 249 postmenopausal women who are breast cancer survivors. This report was an analysis of baseline data from a federally funded (1 R01 NR07743-01A1) intervention study on osteoporosis prevention. Mean age of the women was 58.5 years, and average BMI was 26.7 kg/m; 98% were white. All had measurable bone loss, 167 had chemotherapy, 76 were on tamoxifen, and 21 were on aromatase inhibitors. Women with higher BMI had higher BMD at the hip (P < .001) and the spine (P = .004). Women on tamoxifen had lower measures of bone formation (Alkphase B) (P < .001), suggesting less bone turnover, and higher BMD at the hip (P = .035). There was a trend for women who had received chemotherapy to have lower BMD at the spine (P = .06). The implications of these findings are discussed in the article.

Original languageEnglish (US)
Pages (from-to)182-190
Number of pages9
JournalCancer Nursing
Volume31
Issue number3
DOIs
StatePublished - May 1 2008

Fingerprint

Bone Remodeling
Bone Density
Breast Neoplasms
Bone and Bones
Tamoxifen
Osteoporosis
Drug Therapy
Aromatase Inhibitors
Spine
Body Mass Index
Menopause
Hip
Pelvic Bones
Osteogenesis
Survivors
Estrogens
Multivariate Analysis

Keywords

  • Bone mineral density
  • Bone turnover
  • Breast cancer treatments
  • Postmenopausal women

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

Bone mineral density and bone turnover in postmenopausal women treated for breast cancer. / Waltman, Nancy Lauraine; Ott, Carol D.; Twiss, Janice J; Gross, Gloria J.; Lindsey, Ada M.; Moore, Timothy Eisdell.

In: Cancer Nursing, Vol. 31, No. 3, 01.05.2008, p. 182-190.

Research output: Contribution to journalArticle

@article{bc838e7452024e73bf151d8fc058f096,
title = "Bone mineral density and bone turnover in postmenopausal women treated for breast cancer",
abstract = "Chemotherapy and endocrine treatments for breast cancer are believed to increase risk of osteoporosis by causing early menopause in premenopausal women and by further depleting estrogen levels in postmenopausal women. Multivariate analyses were used to evaluate the contributions of 7 predictors (age, body mass index [BMI], family history of osteoporosis, months since menopause, past use of chemotherapy, and current use of tamoxifen or aromatase inhibitors) in explaining variability in bone mineral density (BMD) at the hip and the spine and bone turnover in 249 postmenopausal women who are breast cancer survivors. This report was an analysis of baseline data from a federally funded (1 R01 NR07743-01A1) intervention study on osteoporosis prevention. Mean age of the women was 58.5 years, and average BMI was 26.7 kg/m; 98{\%} were white. All had measurable bone loss, 167 had chemotherapy, 76 were on tamoxifen, and 21 were on aromatase inhibitors. Women with higher BMI had higher BMD at the hip (P < .001) and the spine (P = .004). Women on tamoxifen had lower measures of bone formation (Alkphase B) (P < .001), suggesting less bone turnover, and higher BMD at the hip (P = .035). There was a trend for women who had received chemotherapy to have lower BMD at the spine (P = .06). The implications of these findings are discussed in the article.",
keywords = "Bone mineral density, Bone turnover, Breast cancer treatments, Postmenopausal women",
author = "Waltman, {Nancy Lauraine} and Ott, {Carol D.} and Twiss, {Janice J} and Gross, {Gloria J.} and Lindsey, {Ada M.} and Moore, {Timothy Eisdell}",
year = "2008",
month = "5",
day = "1",
doi = "10.1097/01.NCC.0000305722.75647.26",
language = "English (US)",
volume = "31",
pages = "182--190",
journal = "Cancer Nursing",
issn = "0162-220X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Bone mineral density and bone turnover in postmenopausal women treated for breast cancer

AU - Waltman, Nancy Lauraine

AU - Ott, Carol D.

AU - Twiss, Janice J

AU - Gross, Gloria J.

AU - Lindsey, Ada M.

AU - Moore, Timothy Eisdell

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Chemotherapy and endocrine treatments for breast cancer are believed to increase risk of osteoporosis by causing early menopause in premenopausal women and by further depleting estrogen levels in postmenopausal women. Multivariate analyses were used to evaluate the contributions of 7 predictors (age, body mass index [BMI], family history of osteoporosis, months since menopause, past use of chemotherapy, and current use of tamoxifen or aromatase inhibitors) in explaining variability in bone mineral density (BMD) at the hip and the spine and bone turnover in 249 postmenopausal women who are breast cancer survivors. This report was an analysis of baseline data from a federally funded (1 R01 NR07743-01A1) intervention study on osteoporosis prevention. Mean age of the women was 58.5 years, and average BMI was 26.7 kg/m; 98% were white. All had measurable bone loss, 167 had chemotherapy, 76 were on tamoxifen, and 21 were on aromatase inhibitors. Women with higher BMI had higher BMD at the hip (P < .001) and the spine (P = .004). Women on tamoxifen had lower measures of bone formation (Alkphase B) (P < .001), suggesting less bone turnover, and higher BMD at the hip (P = .035). There was a trend for women who had received chemotherapy to have lower BMD at the spine (P = .06). The implications of these findings are discussed in the article.

AB - Chemotherapy and endocrine treatments for breast cancer are believed to increase risk of osteoporosis by causing early menopause in premenopausal women and by further depleting estrogen levels in postmenopausal women. Multivariate analyses were used to evaluate the contributions of 7 predictors (age, body mass index [BMI], family history of osteoporosis, months since menopause, past use of chemotherapy, and current use of tamoxifen or aromatase inhibitors) in explaining variability in bone mineral density (BMD) at the hip and the spine and bone turnover in 249 postmenopausal women who are breast cancer survivors. This report was an analysis of baseline data from a federally funded (1 R01 NR07743-01A1) intervention study on osteoporosis prevention. Mean age of the women was 58.5 years, and average BMI was 26.7 kg/m; 98% were white. All had measurable bone loss, 167 had chemotherapy, 76 were on tamoxifen, and 21 were on aromatase inhibitors. Women with higher BMI had higher BMD at the hip (P < .001) and the spine (P = .004). Women on tamoxifen had lower measures of bone formation (Alkphase B) (P < .001), suggesting less bone turnover, and higher BMD at the hip (P = .035). There was a trend for women who had received chemotherapy to have lower BMD at the spine (P = .06). The implications of these findings are discussed in the article.

KW - Bone mineral density

KW - Bone turnover

KW - Breast cancer treatments

KW - Postmenopausal women

UR - http://www.scopus.com/inward/record.url?scp=43249116333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249116333&partnerID=8YFLogxK

U2 - 10.1097/01.NCC.0000305722.75647.26

DO - 10.1097/01.NCC.0000305722.75647.26

M3 - Article

C2 - 18453874

AN - SCOPUS:43249116333

VL - 31

SP - 182

EP - 190

JO - Cancer Nursing

JF - Cancer Nursing

SN - 0162-220X

IS - 3

ER -